World's Best Scientists 2026 revealed!
Melanoma Research
H-index 16

Melanoma Research

0960-8931

Published by: Wolters Kluwer Health, Inc.

https://journals.lww.com/melanomaresearch/pages/default.aspx

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 1649 100 92 15

Additional Metrics

Number of Best Scientists*: 160
Documents by Best Scientists*: 130
Top 100 Ranked Scientists*: 5
SCIMAGO H-index: 82
SCIMAGO SJR: 0.657
Impact Factor: 1.9

Overview

Top Research Topics at Melanoma Research?

Melanoma, Cancer research, Internal medicine, Oncology and Dermatology are among the topics commonly tackled in Melanoma Research. Cutaneous melanoma is part of Melanoma studies tackled in Melanoma Research. While Cancer research is the focus of the journal, it also provided insights into the studies of Immunology, Cell culture, Gene and Apoptosis.

Many of the studies tackled connect Cell culture with a similar field of study like Molecular biology. The featured Internal medicine research zeroes in on concepts in Chemotherapy, Metastatic melanoma and Cancer but also tackles themes under In patient. Immunohistochemistry is a major topic of Pathology research presented in it.

  • Melanoma (56.90%)
  • Cancer research (27.18%)
  • Internal medicine (22.83%)

What are the most cited papers published in the journal?

  • Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. (422 citations)
  • How much melanoma is caused by sun exposure (396 citations)
  • NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing (273 citations)

Research areas of the most cited articles at Melanoma Research:

The most cited publications cover a variety of subjects, including Melanoma, Cancer research, Internal medicine, Oncology and Cutaneous melanoma. While work presented in the most cited publications provide substantial information on Melanoma, it also covers topics in Cell culture, Surgery, Dermatology, Pathology and Metastasis. The works on Cancer research tackled in the journal articles bring together disciplines like Apoptosis, Cell cycle, Regulation of gene expression and Cell growth.

What topics the last edition of the journal is best known for?

  • Internal medicine
  • Cancer
  • Gene

The previous edition focused in particular on these issues:

The journal investigates areas of study like Melanoma, Internal medicine, Oncology, Cancer research and Adverse effect. Melanoma research presented is mostly focused on the subject of Cutaneous melanoma. While the primary focus in the journal is Internal medicine, it also dissects topics surrounding Gastroenterology and Trametinib as a whole.

Melanoma Research deals with Oncology in conjunction with Disease and similar fields in Systemic therapy. The Cancer research studies discussed in it incorporate research from disciplines like

  • Cell culture which intersects with area such as Carcinogenesis,
  • Immunohistochemistry that connect with fields like Cancer stem cell.. Concepts in Adjuvant, as well as related topics in Adjuvant therapy, are covered in the Adverse effect research presented in the journal.

The most cited articles from the last journal are:

  • Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). (4 citations)
  • The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. (3 citations)
  • MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas. (2 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Melanoma Research (based on the number of publications) are:

  • John F. Thompson (57 papers) published 2 papers at the last edition, 1 more than at the previous edition,
  • Claus Garbe (54 papers) absent at the last edition,
  • Hubert Pehamberger (39 papers) absent at the last edition,
  • Johan Hansson (37 papers) absent at the last edition,
  • Reinhard Dummer (35 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Melanoma Research (based on the number of publications) are:

  • University of Texas MD Anderson Cancer Center (60 papers) absent at the last edition,
  • University of Sydney (38 papers) published 3 papers at the last edition, 1 less than at the previous edition,
  • University of Pittsburgh (34 papers) published 4 papers at the last edition, 3 more than at the previous edition,
  • Netherlands Cancer Institute (31 papers) published 3 papers at the last edition, 1 less than at the previous edition,
  • University of Florence (28 papers) absent at the last edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 24.42% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 20.00% were posted by at least one author from the top 10 institutions publishing in the journal. Another 12.31% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 1.54% of all publications and 66.15% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Pathways in Melanoma Research

In addition to the scholarly pursuits within the field of Melanoma Research, it's important to highlight the potential career pathways for those interested in making impactful contributions as practitioners within the healthcare sector. For instance, registered nurses play a significant role in patient care and are often involved in the latest research initiatives in the field. Assuming such a role demands rigorous training and study. If you are considering a career path in nursing and are specifically interested in contributing to the field of melanoma research within the healthcare industry, discovering how to become a registered nurse in Arkansas online could be one feasible starting point. This career path often entails engaging in research undertakings, providing care for patients undergoing various treatments including those for melanoma, participating in educating the public on preventive measures, and frequently working collaboratively with cross-disciplinary teams, thus further enriching your professional experiences. By becoming a registered nurse, not only do you get to directly involve yourself in the medical aspects, but you also get to contribute significantly to research in melanoma -- providing a rich blend of practice-orientated and research-focused career.

Top Publications

  • Estimated risk of progression of lentigo maligna to lentigo maligna melanoma.

    Scott W. Menzies;Sakitha Liyanarachchi;Elliot Coates;Annika Smith

    (2020)
    47 Citations
  • Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma.

    Thijs T Wind;Ranko Gacesa;Arnau Vich Vila;Jacco J de Haan

    (2020)
    46 Citations
  • Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

    Jesus Vera Aguilera;Jonas Paludo;Robert R. McWilliams;Henan Zhang

    (2020)
    43 Citations
  • Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).

    Elisa A Rozeman;Warner Prevoo;Mark A J Meier;Karolina Sikorska

    (2020)
    41 Citations
  • Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).

    Victoria Atkinson;Shahneen Sandhu;Geke Hospers;Georgina V Long

    (2020)
    32 Citations
  • Ultraviolet radiation and cutaneous melanoma: a historical perspective.

    Philippe Autier;Jean-François Doré

    (2020)
    27 Citations
  • Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.

    Cory Kosche;Molly Stout;Jeffrey Sosman;Rimas V. Lukas

    (2020)
    27 Citations
  • Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.

    Michael A Postow;Scott D Chasalow;Deborah Kuk;Katherine S Panageas

    (2020)
    21 Citations
  • Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma

    (2022)
    19 Citations
  • Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).

    F Stephen Hodi;Paul B Chapman;Mario Sznol;Christopher D Lao

    (2021)
    19 Citations

Related Online Degrees & Career Pathways

For those interested in expanding their medical career options beyond traditional MD programs, there are numerous related online degrees worth exploring. For example, pursuing an cheapest online mba healthcare management allows students to combine medical knowledge with essential leadership skills, opening doors to administrative roles within healthcare organizations.

If clinical practice interests you but you are not a nurse, consider accelerated nursing programs for non nurses online. These programs fast-track the process of becoming a registered nurse, providing a strong foundation for further specialization.

One promising nursing specialization is becoming a psychiatric nurse practitioner, a role in high demand. Understanding how much does a psychiatric nurse practitioner make can help you evaluate if this career path aligns with your financial and professional goals.

For those eager to advance quickly, knowing how many years to become a nurse practitioner is vital. Many accelerated pathways enable dedicated students to enter this vital healthcare role in a relatively short period.

Best Scientists Contributing to This Journal

Recently Published Articles